found that consumption of diet rich in cocoa, but not tea drinking, reduced blood pressure, confirming the potential favourable effect of polyphenols and other food components derived from cocoa and cocoa extracts on risk of cardiovascular diseases. However, the possible association between consumption of chocolate and risk of cardiovascular disease has not been adequately studied. To our knowledge, only a cohort study based on 470 men and 314 deaths, including 152 deaths for cardiovascular disease, analysed the issue (Buijsse et al., 2006). That study showed an inverse association between cocoa intake and blood pressure, cardiovascular and all cause mortality (Buijsse et al., 2006). We investigated the issue considering data from a casecontrol study on acute myocardial infarction (AMI), including a specific question on consumption of chocolates and bars of chocolate (Tavani et al., 2006).
Compared to the consumption of o2 chocolates per day, the multivariate OR was 0.49 (95% CI: 0.22-1.10) for 2, and 0.23 (95% CI: 0.08-0.65) for X3 chocolates/day (w 2 trend ¼ 10.57, P ¼ 0.001). The OR for an increment of one chocolate per day was 0.81 (95% CI: 0.69-0.96). In our study, the FFQ was satisfactorily valid and reproducible (Spearman's correlation coefficient for intake frequency of chocolate consumption was 0.47), cases and controls were interviewed in the same hospitals and came from the same geographic area, participation was over 95%, and a different recall of chocolate consumption on the basis of the disease status is unlikely.
These data confirm findings from small intervention studies showing that cocoa-containing foods protect against cardiovascular mortality (Buijsse et al., 2006; Taubert et al., 2007 I was pleased to read the original article entitled 'Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial' published in the European Journal of Clinical Nutrition in 2007 (61:54-60) of a Brazilian group directed by Professor Gontijo-Amaral. Their conclusion was that the oral magnesium (Mg) supplementation helped to reduce bronchial reactivity to metacholine, to diminish the allergen-induced skin responses and to provide better symptom control in pediatric patients with moderate persistent asthma treated with inhaled fluticasone. The authors have mentioned that their study was the first performed in children aiming to investigate the effects of oral magnesium given on a regular basis.
Let me bring to your notice that our paper entitled 'Urinary magnesium excretion in asthmatic children receiving magnesium supplementation: a randomized, placebo-controlled, double-blind study' was published in Magnesium Research in 2003 (16 (4):262-270). The aim of our study was to establish whether a Mg deficit is indicated by a decreased urinary Mg excretion and to determine whether continuous oral Mg supplementation over a 12-week period affects the Mg status, bronchodilator use, clinical symptoms and lung function in 89 randomized atopic children aged 4-16 years with stable bronchial asthma.
The investigation ran over three 4-week treatment periods. During an initial 4-week period and the treatment period, the children ate their normal diet and short-term inhaled b2-mimetics were administered if necessary. All of the patients met the inclusion criteria.
At each visit they received placebo or Mg capsules according to a randomized, double-blinded protocol for the next 4-week period. The Mg intake was predetermined according to age within the groups. Children p7 years old received 200 mg, and children 47 years old received 290 mg Mg citrate daily (National Research Council (US), 1989), or 260 mg glucose as a placebo, in capsule form each evening.
A significant decrease in daytime symptoms was experienced at 8 weeks in the Mg-treated patients which persisted at the end of the study.
The bronchodilator was used significantly more often after 8 and 12 weeks in the placebo groups than in the Mg-treated patients with moderate asthma.
We evaluated the alteration of the forced expiratory volume in 1 second (FEV1) during the study. FEV1 was significantly increased in the Mg group at 4 weeks and even higher at 12 weeks. Almost in parallel, a significant increase in FEV1 was also observed in the placebo-treated group at 8 weeks, which persisted at the end of the study.
Magnesium deficiency resulting from an insufficient Mg intake develops in placebo-treated children with moderate asthma. In addition, b2-mimetic use proved significantly more frequent in placebo-treated than in Mg-treated moderately asthmatic children. b-Adrenergic agonists can stimulate Mg efflux in peripheral tissues (Khilnani et al., 1992; Romani and Scarpa, 1992; Ianello et al., 1998) , which can aggravate the Mg deficit of the cells indicating a certain degree of Mg depletion. Determination of the 24-h urine Mg excretion is an important and simple way to assess a Mg deficiency.
A suboptimal intake of dietary nutrients such as Mg was recently recognized to be a potential risk factor for asthma, especially in childhood (Baker and Ayres, 2000; Hijazi et al., 2000) . Our study demonstrated that a large oral dose of Mg (with an atoxic nature) did not cause any disturbances. The Mg requirements may be greater in growing children, especially those with asthma.
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